FDA approves ZANVASTRO for Alexander disease, broad access label
ZANVASTRO received early FDA approval as the first disease-modifying therapy for Alexander disease, with a broad label for children and adults. The pivotal trial reported motor function stabilization and a favorable safety profile.
ZANVASTRO received early FDA approval as the first disease-modifying therapy for Alexander disease, with a broad label covering children and adults. The pivotal trial showed significant motor function stabilization and a favorable safety profile. Launch efforts are focusing on patient access and support programs.